<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-0255</journal-id>
<journal-title><![CDATA[Revista Archivo Médico de Camagüey]]></journal-title>
<abbrev-journal-title><![CDATA[Arch méd Camagüey]]></abbrev-journal-title>
<issn>1025-0255</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-02552023000100054</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización de pacientes con hepatitis C que recibieron tratamiento con drogas antivirales de acción directa]]></article-title>
<article-title xml:lang="en"><![CDATA[Characterization of patients with hepatitis C who received treatment with direct-acting antiviral drugs]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Menéndez-Placeres]]></surname>
<given-names><![CDATA[Iluminada]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín-Díaz]]></surname>
<given-names><![CDATA[Geidy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-González]]></surname>
<given-names><![CDATA[Marelen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Heredia]]></surname>
<given-names><![CDATA[Odalys Irmina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro-Vega]]></surname>
<given-names><![CDATA[Néstor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jacob-Pérez]]></surname>
<given-names><![CDATA[Yunaika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas Centro Provincial de Higiene, Epidemiología y Microbiología Departamento de Epidemiología.]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas Hospital Clínico Quirúrgico Docente Amalia Simoni Servicio de Gastroenterología]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>27</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-02552023000100054&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-02552023000100054&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-02552023000100054&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La hepatitis C constituye un problema de salud pública mundial por su prevalencia y progresión a la cronicidad. El tratamiento de la hepatitis C con drogas antivirales de acción directa ha revolucionado la práctica de la hepatología clínica por la posibilidad de curar a la mayoría de los pacientes con tratamientos cortos y sin efectos adversos significativos.  Objetivo:  Caracterizar los pacientes con hepatitis C que recibieron tratamiento con drogas antivirales de acción directa en la provincia Camagüey.  Métodos:  Se realizó un estudio observacional descriptivo, transversal y retrospectivo en la provincia Camagüey durante el período del 4 de enero del año 2021 al 28 de marzo del año 2022. El universo de estudio estuvo constituido por 405 pacientes con diagnóstico de hepatitis C en la provincia. La muestra por 110 pacientes que hicieron tratamiento con ribavirina e interferón pegilado y no resolvieron pues sus cargas siguió detectables. Resultados: Se observó un predominio de los pacientes con hepatitis C en el grupo de edad de 55-59 años, sexo masculino, con 1 a 3 años de diagnosticada la enfermedad. No todos terminaron el tratamiento debido a la ocurrencia de fallecimientos. Los que cumplieron con el uso de las drogas antivirales de acción directa sofosbuvir y daclatasvir durante las 12 semanas, en su gran mayoría sus cargas virales resultaron no detectables fundamentalmente en población, no así en los hemodializados aunque estos disminuyeron sus cifras con relación a las que tenían antes de iniciar el tratamiento.  Conclusiones:  El tratamiento resultó ser efectivo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Hepatitis C constitutes a global public health problem due to its prevalence and progression to chronicity. The treatment of hepatitis C with direct-acting antiviral drugs has revolutionized the practice of clinical hepatology due to the possibility of curing the majority of patients with short treatments and without significant side effects.  Objective: To characterize patients with hepatitis C who received treatment with direct-acting antiviral drugs in Camagüey province.  Methods: A descriptive, cross-sectional and retrospective observational study was carried out in the Camagüey province during the period from January 4th, 2021 to March 28th, 2022. The universe of study consisted of 405 patients diagnosed with hepatitis C in the province. The sample was made up of 110 patients who underwent treatment with ribavirin and pegylated interferon and did not resolve as their charges continued to be detectable.  Results: A predominance of patients with hepatitis C was observed in the age group of 55-59 years, male, with 1 to 3 years of diagnosis of the disease. Not all patients completed treatment due to the occurrence of deaths. Those who complied with the use of the direct-acting antiviral drugs sofosbuvir and daclatasvir during the 12 weeks, the vast majority of their viral loads were not detectable, mainly in the population, not so in the hemodialysis patients, although their figures decreased in relation to those who they had before starting treatment.  Conclusions: The treatment turned out to be effective.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[HEPATITIS C/tratamiento farmacológico]]></kwd>
<kwd lng="es"><![CDATA[REACCIÓN EN CADENA DE LA POLIMERASA]]></kwd>
<kwd lng="es"><![CDATA[COINFECCIÓN]]></kwd>
<kwd lng="es"><![CDATA[ANTIVIRALES]]></kwd>
<kwd lng="es"><![CDATA[RESULTADO DEL TRATAMIENTO]]></kwd>
<kwd lng="en"><![CDATA[HEPATITIS C/drug therapy]]></kwd>
<kwd lng="en"><![CDATA[POLYMERASE CHAIN REACTION]]></kwd>
<kwd lng="en"><![CDATA[COINFECTION]]></kwd>
<kwd lng="en"><![CDATA[ANTIVIRAL AGENTS]]></kwd>
<kwd lng="en"><![CDATA[TREATMENT OUTCOME]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sotera]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Salmon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sordá]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revinculación de pacientes con hepatitis C en el contexto de COPVID-19]]></article-title>
<source><![CDATA[Acta Gastroenterol Latinoam]]></source>
<year>2022</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ledezma-Morales]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Trillos]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de pacientes con hepatitis C crónica tratados en un hospital de alta complejidad de Medellín]]></article-title>
<source><![CDATA[Rev Colomb Gastroenterol]]></source>
<year>2019</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalvo Villalba]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Lay]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[López Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bello Corredor]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Montesino]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero Sánchez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del desempeño clínico del ensayo SUMASIGNAL VHC para la detección del ARN del virus de la hepatitis C]]></article-title>
<source><![CDATA[Rev cuban med trop]]></source>
<year>2021</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dávalos Moscol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tagle Arróspide]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Padilla Machaca]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montes Teves]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia peruana en el tratamiento de hepatitis crónica C con las nuevas drogas antivirales de acción directa]]></article-title>
<source><![CDATA[Rev gastroenterol Perú]]></source>
<year>2019</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Razavi]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Epidemiology of Viral Hepatitis]]></article-title>
<source><![CDATA[Gastroenterol Clin North Am]]></source>
<year>2020</year>
<volume>49</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>179-89</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cepeda]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Astemborski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Gicquelais]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs: A Longitudinal, Community-Based Cohort Study]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2022</year>
<volume>175</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1083-91</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas Peláez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo Pérez]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes Escobar]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Bembibre Mozo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Algunas consideraciones sobre las hepatitis virales crónicas como problema de salud]]></article-title>
<source><![CDATA[Medisan]]></source>
<year>2021</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Osorio]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Usme-Ciro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización del Virus de la Hepatitis C en pacientes con historia transfusional antes de 1996 en Colombia]]></article-title>
<source><![CDATA[Iatreia]]></source>
<year>2020</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S20-S1</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ledezma-Morales]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Cárdenas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duque-Zapata]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar-Ospina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ceballos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de pacientes con hepatitis C crónica atendidos bajo un modelo de atención en salud que integra servicios profesionales farmacéuticos asistenciales.]]></article-title>
<source><![CDATA[Farm Comunitarios]]></source>
<year>2020</year>
<volume>12</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matos Morejón]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Cómo se comportan las hepatitis en Cuba?]]></article-title>
<source><![CDATA[MINSAP]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sotoca-Momblona]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Reyes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pagés-Puigdemont]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bartres-Viñas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Tajes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lens-García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica]]></article-title>
<source><![CDATA[Ars Pharm]]></source>
<year>2020</year>
<month> E</month>
<day>ne</day>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ajwad Butt]]></surname>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shaikh]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Re]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abou-Samra]]></surname>
</name>
<name>
<surname><![CDATA[Sherman]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ER-CHIVES study]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-84</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Rodríguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Morejón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cedeño Díaz]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Guada Delgado]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de pacientes con Hepatitis C en el servicio de hemodiálisis, Cienfuegos 2019]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2021</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>220-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Ortega]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera Corrales]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Calderín Pino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Caloto]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Betancourt Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Cruz]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapia antiviral de acción directa para infección del virus de hepatitis C en pacientes en hemodiálisis]]></article-title>
<source><![CDATA[Rev cuba hig epidemiol]]></source>
<year>2023</year>
<volume>60</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Silva Leite]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[De Oliveira Inácio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Melo Monteiro]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Da Câmara Marques]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro Barreto]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues Feijão]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización sociodemográfica y clínica de pacientes portadores de hepatitis C crónica]]></article-title>
<source><![CDATA[Enferm glob]]></source>
<year>2019</year>
<volume>18</volume>
<numero>55</numero>
<issue>55</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Steinbrecher]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tavella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Warley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la hepatitis C en el conurbano de Buenos Aires]]></article-title>
<source><![CDATA[Medicina]]></source>
<year>2021</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Das Chagas Borges Neto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato de Souza]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Barata Novaes]]></surname>
<given-names><![CDATA[ICR]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa da Silveira]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pantoja Nunes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Melo Miranda]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad del tratamiento con drogas antivirales de acción directa en pacientes con hepatitis C atendidos en un centro de referencia en el estado de Pará, Brasil, de 2017 a 2019]]></article-title>
<source><![CDATA[Rev Pan Amaz Saude]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meroño-Saura]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ibañez-Caturla]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Martínez]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco-López]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza-Aniorte]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[León Villar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados en vida real de los antivirales de acción directa en el tratamiento de la hepatitis C crónica]]></article-title>
<source><![CDATA[Rev OFIL ILAPHAR]]></source>
<year>2021</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cárdaba García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Antivirales de acción directa frente al virus de la hepatitis C: efectividad e impacto de las intervenciones farmacéuticas realizadas durante el seguimiento farmacoterapéutico]]></source>
<year>2022</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otegui]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Olivari]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mainardi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gerona]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implementación de una estrategia de revinculación a la atención en pacientes con infección crónica por el virus de la hepatitis C en el Hospital Central de las Fuerzas Armadas de Uruguay. Resultados preliminares]]></article-title>
<source><![CDATA[Rev Urug Med Int]]></source>
<year>2022</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charatcharoenwitthaya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wongpaitoon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Komolmit]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sukeepaisarnjaroen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tangkijvanich]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Piratvisuth]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study]]></article-title>
<source><![CDATA[BMC Gastroenterol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>47</numero>
<issue>47</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosia]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[D´Ascenzo]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Borzi]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Barán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Calzona]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de hepatitis crónica por virus de Hepatitis C con drogas antivirales de acción directa en un paciente con fibrosis quística]]></article-title>
<source><![CDATA[Acta Gastroenterol Latinoam]]></source>
<year>2021</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopera]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya-Guzmán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Posada]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la infección del virus de la hepatitis C: de la terapia con interferón a los antivirales de acción directa]]></article-title>
<source><![CDATA[IATREIA]]></source>
<year>2023</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridruejo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mendizabal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento simplificado de la hepatitis C: otra estrategia para superar las barreras hacia su eliminación.]]></article-title>
<source><![CDATA[MEDICINA]]></source>
<year>2021</year>
<volume>81</volume>
<page-range>252-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seoane Blanco]]></surname>
</name>
<name>
<surname><![CDATA[Soto Sánchez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra Dorado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parapar Álvarez]]></surname>
</name>
<name>
<surname><![CDATA[Crespo Sánchez]]></surname>
</name>
<name>
<surname><![CDATA[Sánchez Domínguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Búsqueda activa de pacientes con hepatitis C en atención primaria]]></article-title>
<source><![CDATA[Rev Española Enferm Digest]]></source>
<year>2021</year>
<volume>113</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>820-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
